4 unknown. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Unknown 4 |
Follow HER-2 Gene Amplification: new trials by email Literature Review of HER-2 Gene Amplification trials Research Report on HER-2 Gene Amplification
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma Trastuzumab - Carcinoma, Transitional Cell, HER-2 Gene Amplification | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 30 | 2022-03-10 | 2022-04-08 |
| Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients Trastuzumab - Esophageal Squamous Cell Carcinoma, HER-2 Protein Overexpression | Phase 2 | Unknown | Morten Mau-Sørensen | 24 | 2022-02-04 | 2022-08-12 |
| Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor Trastuzumab biosimilar, Gemcitabine Hydrochloride, Irinotecan Hydrochloride - HER-2 Protein Overexpression, HER-2 Gene Amplification | Phase 2 | Unknown | Jin-Hee Ahn | 42 | 2019-12-30 | 2020-01-02 |
| The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor Pyrotinib - Solid Tumor, HER2 Gene Mutation | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 100 | 2019-12-01 | 2019-11-27 |
Carcinoma, Transitional Cell (1) · Esophageal Squamous Cell Carcinoma (1)
Carcinoma (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Carcinoma, Squamous Cell (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Esophageal Diseases (1) · Esophageal Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Head and Neck Neoplasms (1) · Neoplasms by Site (1) · Neoplasms, Squamous Cell (1)
Trastuzumab (2) · pyrotinib (2) · Gemcitabine (1) · Irinotecan (1)
Chinese Academy of Medical Sciences (1) · Jin-Hee Ahn (1) · Morten Mau-Sørensen (1) · Tianjin Medical University Second Hospital (1)
China (2) · Denmark (1)
Haitao Wang (1) · Lene Baeksgaard, MD PhD (1)